ProCE Banner Activity

ExpressPoints Precision Medicine Advances in Early Breast Cancer: Experts Discuss the Expanding Role of Biomarkers to Guide Neo/Adjuvant Therapy

Slideset Download
Download this short summary slideset to review key takeaways on perioperative treatment of early breast cancer.

Released: December 16, 2022

Expiration: December 15, 2023

No longer available for credit.
Begin Activity

Share

Faculty

Melinda Telli

Melinda Telli, MD

Professor Of Medicine
Stanford University School of Medicine
Director, Breast Cancer Program
Stanford Cancer Institute
Palo Alto, California

Tiffany A. Traina

Tiffany A. Traina, MD

Assistant Attending
Breast Medicine Service
Memorial Sloan Kettering Cancer Center
Assistant Professor
Department of Medicine
Weill Medical College of Cornell University
New York, New York

Provided by

Provided by Clinical Care Options, LLC.
ProCE Banner

Supporters

AstraZeneca Pharmaceuticals

Lilly

Merck Sharp & Dohme, LLC

Sanofi

Faculty Disclosure

Primary Author

Melinda Telli, MD

Professor Of Medicine
Stanford University School of Medicine
Director, Breast Cancer Program
Stanford Cancer Institute
Palo Alto, California

Melinda Telli, MD: consultant/advisor: AstraZeneca, Blueprint Medicines, Daiichi Sankyo, Genentech/Roche, G1 Therapeutics, Gilead Sciences, GlaxoSmithKline, Guardant, Immunomedics, Lilly, Merck, Natera, Novartis, Pfizer, RefleXion, Sanofi; researcher (paid to institution): AbbVie, Bayer, Biothera, Calithera Biosciences, EMD Serono, Genentech, GlaxoSmithKline, Hummingbird Biosciences, Medivation, Novartis, OncoSec, Pfizer, PharmaMar, Tesaro, Vertex.

Tiffany A. Traina, MD

Assistant Attending
Breast Medicine Service
Memorial Sloan Kettering Cancer Center
Assistant Professor
Department of Medicine
Weill Medical College of Cornell University
New York, New York

Tiffany A. Traina, MD: consultant/advisor/speaker: AstraZeneca, Merck; researcher: AstraZeneca.